Kirkland & Ellis advised investment firm Altaris, LLC on the pending acquisition of Minaris Regenerative Medicine from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004). Minaris is a cell therapy contract development and manufacturing organization that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers globally. The transaction is expected to close in the first quarter of 2025 subject to customary closing conditions.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
